Glaukos Delivers Record Q1 2026 Sales and Raises Full-Year Guidance on Glaucoma Division Strength
Q1 2026 Sales Growth Surpasses Expectations With U.S. Glaucoma Leading the Charge
Glaukos (NYSE: GKOS) has kicked off 2026 with a breakout quarter, reporting record net sales of $150.6 million—a 41% year-over-year climb. The standout segment: U.S. glaucoma therapies, which surged 58% year-over-year to $93.5 million, setting a new high-water mark for the division. International glaucoma sales, meanwhile, delivered solid double-digit expansion. In response to this momentum, management has raised their full-year sales outlook to a range of $620 million to $635 million, up from the previous $600 million to $620 million guidance.
| Key Segment | Q1 2026 Net Sales ($M) | YoY Change (%) |
|---|---|---|
| Total Net Sales | 150.6 | 41.2% |
| Glaucoma (Total) | 129.3 | 47.0% |
| U.S. Glaucoma | 93.5 | 58.0% |
| International Glaucoma | 35.8 | 23.4% |
Gross Margins Remain Strong, Underpinning Growth Investments
Gross margin for Q1 clocked in at roughly 78% on a GAAP basis and an impressive 84% on a non-GAAP basis—ticking higher from last year’s 77% (GAAP) and 82% (non-GAAP). This expansion gives Glaukos room to support hefty R&D (+36% YoY) and SG&A (+32% YoY) investments, fueling the ramp-up of novel products like iDose TR and Epioxa for chronic eye disease. Management cited these dropless platform technologies as transformational growth engines for the firm going forward.
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Gross Margin (GAAP) | 77.9% | 77.2% |
| Gross Margin (Non-GAAP) | 83.6% | 82.4% |
| SG&A (Non-GAAP, $M) | 92.2 | 70.7 |
| R&D (GAAP & Non-GAAP, $M) | 44.1 | 32.4 |
Operating Loss Narrows on a Non-GAAP Basis Amid Continued Strategic Investments
While Glaukos reported a GAAP net loss for Q1 2026 of $19.8 million (or $0.34 per diluted share), the company managed to sharply reduce its non-GAAP operating loss to $10.5 million versus $15.2 million a year ago. Similarly, non-GAAP net loss was $10.4 million (or $0.18 per share), an improvement on last year’s $12.6 million ($0.22 per share). The narrowing non-GAAP deficit suggests underlying operational progress, with management using margin strength to aggressively pursue pipeline programs and market expansion.
| Profitability Metrics | Q1 2026 | Q1 2025 |
|---|---|---|
| GAAP Net Loss ($M) | -19.8 | -18.1 |
| Non-GAAP Net Loss ($M) | -10.4 | -12.6 |
| Non-GAAP EPS | -0.18 | -0.22 |
Cash Position and Guidance Provide a Safety Net for Continued Expansion
Glaukos exited the quarter with $280.5 million in cash, short-term investments, and restricted cash—and crucially, remains debt-free. With raised full-year revenue guidance and a strengthening core franchise, the company is signaling confidence in both near-term execution and medium-term pipeline milestones. Investors will likely tune in to today’s webcast for more insights into management’s vision for runway length and capital allocation.
What Does It Mean for Investors?
Despite ongoing accounting losses, Glaukos’s surging sales, widening margins, and robust cash reserves paint a picture of a company still in growth mode but laying the groundwork for long-term profitability. With novel therapies beginning to scale and the glaucoma platform firing on all cylinders, the story now hinges on continued execution—and whether Glaukos’s pipeline can deliver the next leg of growth in a competitive, innovation-driven space.
For investors, the story going forward remains: Can Glaukos sustain momentum in glaucoma, successfully commercialize its new products, and turn record sales gains into sustainable profits? The market will be watching for signs that this early 2026 performance isn’t just a one-off, but a harbinger of a new period of value creation.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI